One icodextrin exchange

PreclinicalSmall molecule

NNational University Health System, Singapore

One icodextrin exchange is one of 21 small molecule programs targeting Blood Pressure. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood PressureNot yet recruiting

Blood PressurePreclinical

Not yet recruiting

Competition

Competitive Landscape

30 competitors in Blood Pressure

#DrugCompanyPhaseTrials

Benicar

Novartis

Phase 3

2 2

Intropin

Pfizer

Preclinical

1 3

Isoproterenol Hydrochloride

Sanofi

Preclinical

1 4

Robinul

Jazz Pharmaceuticals

Preclinical

1 5

Carbocaine

Pfizer

Preclinical

1 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Preclinical

1 8

Atropen

FFresenius Kabi Taiwan Ltd.

Preclinical

1 9

Pitressin

AAultman Health Foundation

Preclinical

1 10

Glypressin

MMallinckrodt

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

N/ANot yet recruiting

Blood Pressure

NCT07168343

Clinical

Trials by Indication[1]

Blood Pressure1 trial

Effectiveness of Two Icodextrin Exchanges on Fluid Status and Blood Pressure Control Compared to a Single Icodextrin Exchange

Not yet recruiting·NNational University Health System, Singapore·N/A·NCT07168343·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for One icodextrin exchange. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — One icodextrin exchange compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for One icodextrin exchange. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University Health System, Singapore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational University Health System, Singapore

One icodextrin exchange

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Blood Pressure1 trial

References

Drug Info

Quick Facts

Related News